{"schemas":{"sample_registration":{"updated":{"program_id":{"meta":{"notes":{"left":"This is the unique id that is assigned to your program.  If you have logged into the platform, this is the Program Id that you see in the Program Services area. For example, TEST-CA is a Program ID.","right":"This is the unique id that is assigned to your program.  If you have logged into the platform, this is the Program Id that you see in the Submission area. For example, PACA-CA is a Program ID."}}},"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_specimen_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_sample_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}}},"created":{},"deleted":{}},"donor":{"updated":{"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}}},"created":{},"deleted":{}},"specimen":{"updated":{"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_specimen_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_primary_diagnosis_id":{"description":{"left":"Indicate the primary diagnosis event in the clinical timeline that this specimen acquisition was related to.","right":"Indicate the primary diagnosis event in the clinical timeline that this specimen aquisition was related to."},"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"pathological_stage_group":{"description":{"left":"Specify the tumour stage, based on pathological_tumour_staging_system, used to assess the cancer at the time the tumour specimen was resected.","right":"Specify the tumour stage, based on tumour_staging_system, used to assess the cancer at the time the tumour specimen was resected."},"meta":{"notes":{"left":"This field depends on the selected pathological_tumour_staging_system, and is only required if the specimen is a tumour.\nPlease refer to the documentation for Tumour Staging Classifications: http://docs.icgc-argo.org/docs/submission/dictionary-overview#tumour-staging-classifications","right":"This field depends on the selected pathological staging system, and is only required if the specimen is a tumour."}}},"specimen_acquisition_interval":{"meta":{"notes":{"left":"The associated primary diagnosis is used as the reference point for this interval. To calculate this, find the number of days since the date of primary diagnosis.","right":"The associated Primary Diagnosis is used as the reference point for this interval. To calculate this, find the number of days since the date of primary diagnosis."},"displayName":{"left":"Specimen Acquisition Interval","right":"Specimen Aquisition Interval"}}},"reference_pathology_confirmed":{"description":{"left":"Indicate whether the pathological diagnosis was confirmed by a (central) reference pathologist.","right":"Indicate whether the pathological diagnosis was confirmed by a (central) reference pathologist. This only applies to clinical studies."}},"tumour_grade":{"meta":{"notes":{"left":"This field depends on the selected tumour_grading_system, and is only required if the specimen is a tumour.\nPlease refer to the documentation for Tumour Grading Classifications: http://docs.icgc-argo.org/docs/submission/dictionary-overview#tumour-grading-classifications","right":"This field depends on the selected tumour grading system, and is only required if the specimen is a tumour."}}}},"created":{},"deleted":{}},"primary_diagnosis":{"updated":{"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_primary_diagnosis_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"age_at_diagnosis":{"description":{"left":"Age that the donor was first diagnosed with cancer, in years. This should be based on the earliest diagnosis of cancer.","right":"Age that the donor was first diagnosed with cancer, in years."}},"clinical_stage_group":{"description":{"left":"Stage group of the tumour, as assigned by the reporting clinical_tumour_staging_system, that indicates the overall prognostic tumour stage (ie. Stage I, Stage II, Stage III etc.).","right":"Stage group of the tumour, as assigned by the reporting tumour_staging_system, that indicates the overall prognostic tumour stage (ie. Stage I, Stage II, Stage III etc.)."},"meta":{"notes":{"left":"This field is dependent on the selected clinical_tumour_staging_system.\nPlease refer to the documentation for Tumour Staging Classifications: http://docs.icgc-argo.org/docs/submission/dictionary-overview#tumour-staging-classifications","right":"This field is dependent on the selected clinical_tumour_staging_system"}},"restrictions":{"required":{"left":true}}},"clinical_n_category":{"description":{"left":"The code to represent the stage of cancer defined by the extent of the regional lymph node (N) involvement for the cancer based on evidence obtained from clinical assessment parameters determined at time of primary diagnosis and prior to treatment, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.","right":"The code to represent the stage of cancer defined by which is the extent of the regional lymph node (N) involvement for the cancer based on evidence obtained from clinical assessment parameters determined at time of primary diagnosis and prior to treatment, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual."}},"clinical_m_category":{"description":{"left":"The code to represent the stage of cancer defined by the extent of the distant metastasis (M) for the cancer based on evidence obtained from clinical assessment parameters determined at time of primary diagnosis and prior to treatment, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual. MX is NOT a valid category and cannot be assigned.","right":"The code to represent the stage of cancer defined bythe extent of the distant metastasis (M) for the cancer based on evidence obtained from clinical assessment parameters determined at time of primary diagnosis and prior to treatment, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual. MX is NOT a valid category and cannot be assigned."}},"presenting_symptoms":{"restrictions":{"codeList":{"left":["Abdominal Pain","Anemia","Back Pain","Bloating","Cholangitis","Constipation","Dark Urine","Decreased Appetite","Diabetes","Diarrhea","Fatigue","Fever","Hypoglycemia","Jaundice","Loss of Appetite","Nausea","None","Pale Stools","Pancreatitis","Pruritus/Itchiness","Steatorrhea","Unknown","Vomiting","Weight Loss"],"right":["Abdominal Pain","Anemia","Back Pain","Bloating","Cholangitis","Constipation","Dark Urine","Decreased Appetite","Diabetes","Diarrhea","Fatigue","Fever","Hypoglycemia","Jaundice","Nausea","None","Pale Stools","Pancreatitis","Pruritus/Itchiness","Steatorrhea","Unknown","Vomiting","Weight Loss"],"data":{"added":[],"deleted":["Loss of Appetite"]}}}},"performance_status":{"meta":{"notes":{"left":"Grade 0: Fully active, able to carry on all pre-disease performance without restriction.\nGrade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (ie. Light house work, office work).\nGrade 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours.\nGrade 3: Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours.\nGrade 4: Completely disabled; cannot carry on any selfcare; totally confined to bed or chair","right":"Grade 0: Fully active, able to carry on all pre-disease performance without restriction \n Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (ie. Light house work, office work) \n Grade 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours \n Grade 3: Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours \n Grade 4: Completely disabled; cannot carry on any selfcare; totally confined to bed or chair"}}}},"created":{},"deleted":{"cancer_type_additional_information":{"changeType":"deleted","name":"cancer_type_additional_information","valueType":"string","description":"Additional details related to the cancer type that are not covered by the ICD-10 code provided in the cancer_type field.","meta":{"displayName":"Cancer Type Additional Information"}}}},"treatment":{"updated":{"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_treatment_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_primary_diagnosis_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"treatment_type":{"meta":{"notes":{"left":"Depending on the treatment_type(s) selected, additional treatment details may be required to be submitted. For example, if treatment_type includes 'Chemotherapy', the supplemental Chemotherapy treatment type file is required.\nTo include multiple values, separate values with a pipe delimiter '|' within your file.","right":"Depending on the treatment_type(s) selected, additional treatment details may be required to be submitted. For example, if treatment_type includes 'Chemotherapy', the supplemental Chemotherapy treatment type file is required."}}},"is_primary_treatment":{"description":{"left":"Indicate if the treatment was the primary treatment following the initial diagnosis.","right":"Indicate if the treamtment was the primary treatment following the initial diagnosis."}},"response_to_therapy":{"description":{"left":"The donor's response to the applied treatment regimen. (Source: RECIST)","right":"The donors's response to the applied treatment regimen. (Source: RECIST)"}},"hemotological_toxicity":{"meta":{"notes":{"left":"To include multiple values, separate values with a pipe delimiter '|' within your file."}}},"adverse_events":{"meta":{"notes":{"left":"To include multiple values, separate values with a pipe delimiter '|' within your file."}}}},"created":{},"deleted":{}},"chemotherapy":{"updated":{"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_treatment_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"drug_rxnormcui":{"meta":{"notes":{"left":"This field uses standardized vocabulary from the RxNorm database (https://www.nlm.nih.gov/research/umls/rxnorm), provided by the NIH.\n\nYou can search for RX Norm values through the web interface (https://mor.nlm.nih.gov/RxNav/) or API (https://mor.nlm.nih.gov/download/rxnav/RxNormAPIs.html).\n\nFor example, to find the rxnormcui based on drug name, you can use: https://rxnav.nlm.nih.gov/REST/rxcui.json?name=leucovorin or https://mor.nlm.nih.gov/RxNav/search?searchBy=String&searchTerm=leucovorin","right":"This field uses standardized vocabulary from the RxNorm database (https://www.nlm.nih.gov/research/umls/rxnorm), provided by the NIH.\n\nYou can search for RX Norm values through the web interface (https://mor.nlm.nih.gov/RxNav/) or API (https://mor.nlm.nih.gov/download/rxnav/RxNormAPIs.html).\n\nFor example, to find the rxnormcui based on drug name, you can use: https://rxnav.nlm.nih.gov/REST/rxcui.json?name=leucovorin"}}},"drug_name":{"meta":{"notes":{"left":"This field uses standardized vocabulary from the RxNorm database (https://www.nlm.nih.gov/research/umls/rxnorm), provided by the NIH.\n\nYou can search for RX Norm values through the web interface (https://mor.nlm.nih.gov/RxNav/) or API (https://mor.nlm.nih.gov/download/rxnav/RxNormAPIs.html).\n\nFor example, to find the rxnormcui based on drug name, you can use: https://rxnav.nlm.nih.gov/REST/rxcui.json?name=leucovorin or https://mor.nlm.nih.gov/RxNav/search?searchBy=String&searchTerm=leucovorin","right":"This field uses standardized vocabulary from the RxNorm database (https://www.nlm.nih.gov/research/umls/rxnorm), provided by the NIH.\n\nYou can search for RX Norm values through the web interface (https://mor.nlm.nih.gov/RxNav/) or API (https://mor.nlm.nih.gov/download/rxnav/RxNormAPIs.html).\n\nFor example, to find the rxnormcui based on drug name, you can use: https://rxnav.nlm.nih.gov/REST/rxcui.json?name=leucovorin"}}}},"created":{},"deleted":{}},"hormone_therapy":{"updated":{"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_treatment_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"drug_rxnormcui":{"meta":{"notes":{"left":"This field uses standardized vocabulary from the RxNorm database (https://www.nlm.nih.gov/research/umls/rxnorm), provided by the NIH.\n\nYou can search for RX Norm values through the web interface (https://mor.nlm.nih.gov/RxNav/) or API (https://mor.nlm.nih.gov/download/rxnav/RxNormAPIs.html).\n\nFor example, to find the rxnormcui based on drug name, you can use: https://rxnav.nlm.nih.gov/REST/rxcui.json?name=leucovorin or https://mor.nlm.nih.gov/RxNav/search?searchBy=String&searchTerm=leucovorin","right":"This field uses standardized vocabulary from the RxNorm database (https://www.nlm.nih.gov/research/umls/rxnorm), provided by the NIH.\n\nYou can search for RX Norm values through the web interface (https://mor.nlm.nih.gov/RxNav/) or API (https://mor.nlm.nih.gov/download/rxnav/RxNormAPIs.html).\n\nFor example, to find the rxnormcui based on drug name, you can use: https://rxnav.nlm.nih.gov/REST/rxcui.json?name=leucovorin"}}},"drug_name":{"meta":{"notes":{"left":"This field uses standardized vocabulary from the RxNorm database (https://www.nlm.nih.gov/research/umls/rxnorm), provided by the NIH.\n\nYou can search for RX Norm values through the web interface (https://mor.nlm.nih.gov/RxNav/) or API (https://mor.nlm.nih.gov/download/rxnav/RxNormAPIs.html).\n\nFor example, to find the rxnormcui based on drug name, you can use: https://rxnav.nlm.nih.gov/REST/rxcui.json?name=leucovorin or https://mor.nlm.nih.gov/RxNav/search?searchBy=String&searchTerm=leucovorin","right":"This field uses standardized vocabulary from the RxNorm database (https://www.nlm.nih.gov/research/umls/rxnorm), provided by the NIH.\n\nYou can search for RX Norm values through the web interface (https://mor.nlm.nih.gov/RxNav/) or API (https://mor.nlm.nih.gov/download/rxnav/RxNormAPIs.html).\n\nFor example, to find the rxnormcui based on drug name, you can use: https://rxnav.nlm.nih.gov/REST/rxcui.json?name=leucovorin"}}}},"created":{},"deleted":{}},"radiation":{"updated":{"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_treatment_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"radiation_therapy_fractions":{"description":{"left":"Indicate the total number of fractions delivered as part of treatment.","right":"Indicate the number of total fractions delivered as part of treatment."}}},"created":{"radiation_treatment_type":{"changeType":"created","name":"radiation_treatment_type","description":"Indicate type of radiation therapy administered.","valueType":"string","restrictions":{"required":true,"codeList":["External","Internal"]},"meta":{"core":true,"displayName":"Application Form","notes":"Internal application includes Brachytherapy."}}},"deleted":{"radiation_therapy_type":{"changeType":"deleted","name":"radiation_therapy_type","description":"Indicate type of radiation therapy administered.","valueType":"string","restrictions":{"required":true,"codeList":["External","Internal"]},"meta":{"core":true,"displayName":"Type of Radiation Therapy","notes":"Internal application includes Brachytherapy."}}}},"follow_up":{"updated":{"submitter_donor_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_follow_up_id":{"description":{"left":"Unique identifier for a follow-up event in a donor's clinical record, assigned by the data provider.","right":"Unique identifier for a follow-up event in a donors clincal record, assigned by the data provider."},"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"interval_of_followup":{"meta":{"notes":{"left":"The associated primary diagnosis is used as the reference point for this interval. To calculate this, find the number of days since the date of primary diagnosis.","right":"The associated Primary Diagnosis is used as the reference point for this interval. To calculate this, find the number of days since the date of primary diagnosis."}}},"disease_status_at_followup":{"description":{"left":"Indicate the donor's disease status at time of follow-up. (Reference: RECIST)","right":"Indicate the donor's disease status at time of follow-up."},"restrictions":{"codeList":{"left":["Complete remission","Distant progression","Loco-regional progression","No evidence of disease","Partial remission","Progression NOS","Relapse or recurrence","Stable"],"right":["Complete remission","Distant progression","Loco-regional progression","No evidence of disease","Partial remission","Relapse or recurrence","Stable"],"data":{"added":[],"deleted":["Progression NOS"]}}}},"submitter_primary_diagnosis_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"submitter_treatment_id":{"meta":{"notes":{"left":"To prevent data collisions, submitter_id cannot begin with any of the ARGO ID prefixes.  The restricted prefixes include: `DO`, `SP`, `SA`,`TR`,`FU`, `PD`."}}},"relapse_interval":{"restrictions":{"script":{"left":["(function validate() {\n        let result = {valid: true, message: \"Ok\"};\n        \n        /* required field, cannot be null */\n        const diseaseStatus = $row.disease_status_at_followup.trim().toLowerCase();\n        const intervalOfFollowup = parseInt($row.interval_of_followup);\n\n        const stateOfProgression = (entry) => {return /(progression)$/.test(decodeURI(entry))}; \n        const relapseOrRecurrence = diseaseStatus === \"relapse or recurrence\";\n   \n        // checks for a string just consisting of whitespace\n        const checkforEmpty = (entry) => {return /^\\s+$/g.test(decodeURI(entry).replace(/^\"(.*)\"$/, '$1'))};\n\n\n        if ((!$field || checkforEmpty($field)) && (stateOfProgression(diseaseStatus) || relapseOrRecurrence)) {\n            result = {valid: false, message: `'${$name}' is a required field if 'disease_status_at_followup' is set a state of progression, relapse, or recurrence.` }\n        }\n        else if (!(!$field || checkforEmpty($field)) && !stateOfProgression(diseaseStatus) && !relapseOrRecurrence) {\n            result = {valid: false, message: `'${$name}' cannot be provided if 'disease_status_at_followup' is not a state of progression, relapse, or recurrence.` }\n        }\n        else if (!(checkforEmpty($field)) && (stateOfProgression(diseaseStatus) || relapseOrRecurrence)) {\n            relapseInterval = parseInt($field);\n            if (relapseInterval > intervalOfFollowup) {\n                result = {valid: false, message: `'${$name}' cannot be greater than the 'interval_of_followup'.` }\n            }\n        }\n        return  result;\n    })()"],"right":["(function validate() {\n        let result = {valid: true, message: \"Ok\"};\n        \n        /* required field, cannot be null */\n        const diseaseStatus = $row.disease_status_at_followup.trim().toLowerCase();\n    \n        const stateOfProgression = (entry) => {return /(progression)$/.test(decodeURI(entry))}; \n        const relapseOrRecurrence = diseaseStatus === \"relapse or recurrence\";\n   \n        // checks for a string just consisting of whitespace\n        const checkforEmpty = (entry) => {return /^\\s+$/g.test(decodeURI(entry).replace(/^\"(.*)\"$/, '$1'))};\n\n\n        if ((!$field || checkforEmpty($field)) && (stateOfProgression(diseaseStatus) || relapseOrRecurrence)) {\n            result = {valid: false, message: `'${$name}' is a required field if 'disease_status_at_followup' is set a state of progression, relapse, or recurrence.` }\n        }\n        else if (!(!$field || checkforEmpty($field)) && !stateOfProgression(diseaseStatus) && !relapseOrRecurrence) {\n            result = {valid: false, message: `'${$name}' cannot be provided if 'disease_status_at_followup' is not a state of progression, relapse, or recurrence.` }\n        }\n        return  result;\n    })()"]}}},"method_of_progression_status":{"meta":{"notes":{"left":"This field is required to be submitted if disease_status_at_followup indicates a state of progression, relapse, or recurrence.\nTo include multiple values, separate values with a pipe delimiter '|' within your file.","right":"This field is required to be submitted if disease_status_at_followup indicates a state of progression, relapse, or recurrence"}}},"anatomic_site_progression_or_recurrences":{"description":{"left":"Indicate the ICD-O-3 topography code for the anatomic site where disease progression, relapse or recurrence occurred, according to the International Classification of Diseases for Oncology, 3rd Edition (WHO ICD-O-3). Refer to the ICD-O-3 manual for guidelines at https://apps.who.int/iris/handle/10665/42344.","right":"Indicate the ICD-O-3 topography code for the anatomic site where disease progression or recurrence occurred, according to the International Classification of Diseases for Oncology, 3rd Edition (WHO ICD-O-3). Refer to the ICD-O-3 manual for guidelines at https://apps.who.int/iris/handle/10665/42344."}},"recurrence_t_category":{"description":{"left":"The code to represent the extent of the primary tumour (T) based on evidence obtained from clinical assessment parameters determined at the time of retreatment for a recurrence or disease progression, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.","right":"The code to represent the extent of the primary tumour (T) based on evidence obtained from clinical assessment parameters determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual."}},"recurrence_n_category":{"description":{"left":"The code to represent the stage of cancer defined by the extent of the regional lymph node (N) involvement for the cancer based on evidence obtained from clinical assessment parameters determined at the time of retreatment for a recurrence or disease progression, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.","right":"The code to represent the stage of cancer defined by which is the extent of the regional lymph node (N) involvement for the cancer based on evidence obtained from clinical assessment parameters determined determined at the time of retreatment for a recurrence or disease progression, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual."}},"recurrence_m_category":{"description":{"left":"The code to represent the stage of cancer defined by the extent of the distant metastasis (M) for the cancer based on evidence obtained from clinical assessment parameters determined at the time of retreatment for a recurrence or disease progression, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.","right":"The code to represent the stage of cancer defined bythe extent of the distant metastasis (M) for the cancer based on evidence obtained from clinical assessment parameters determined determined at the time of retreatment for a recurrence or disease progression, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual."}},"recurrence_stage_group":{"description":{"left":"The code to represent the stage group of the tumour, as assigned by the reporting recurrence_tumour_staging_system, that indicates the overall prognostic tumour stage (ie. Stage I, Stage II, Stage III etc.) at the time of retreatment for a recurrence or disease progression.","right":"The code to represent the stage group of the tumour, as assigned by the reporting recurrence_tumour_staging_system, that indicates the overall prognostic tumour stage (ie. Stage I, Stage II, Stage III etc.) after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery."},"meta":{"notes":{"left":"This field is dependent on the selected recurrence_tumour_staging_system.\nPlease refer to the documentation for Tumour Staging Classifications: http://docs.icgc-argo.org/docs/submission/dictionary-overview#tumour-staging-classifications","right":"This field is dependent on the selected recurrence_tumour_staging_system."}}},"posttherapy_t_category":{"meta":{}},"posttherapy_n_category":{"description":{"left":"The code to represent the stage of cancer defined by the extent of the regional lymph node (N) involvement for the cancer based on evidence obtained from clinical assessment parameters determined determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.","right":"The code to represent the stage of cancer defined by which is the extent of the regional lymph node (N) involvement for the cancer based on evidence obtained from clinical assessment parameters determined determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual."},"meta":{}},"posttherapy_m_category":{"description":{"left":"The code to represent the stage of cancer defined by the extent of the distant metastasis (M) for the cancer based on evidence obtained from clinical assessment parameters determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual.","right":"The code to represent the stage of cancer defined bythe extent of the distant metastasis (M) for the cancer based on evidence obtained from clinical assessment parameters determined determined after treatment for patients receiving systemic and/or radiation therapy alone or as a component of their initial treatment, or as neoadjuvant therapy before planned surgery, according to criteria based on multiple editions of the AJCC's Cancer Staging Manual."},"meta":{}},"posttherapy_stage_group":{"meta":{"notes":{"left":"This field is dependent on the selected posttherapy_tumour_staging_system.\nPlease refer to the documentation for Tumour Staging Classifications: http://docs.icgc-argo.org/docs/submission/dictionary-overview#tumour-staging-classifications","right":"This field is dependent on the selected posttherapy_tumour_staging_system."}}}},"created":{},"deleted":{}}},"counts":{"updated":56,"deleted":2,"created":1}}
